JAK inhibition as a therapeutic strategy for immune and inflammatory diseases,Nature Reviews Drug Discovery

当前位置： X-MOL 学术 › Nat. Rev. Drug. Disc. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Nature Reviews Drug Discovery ( IF 120.1 ) Pub Date : 2017-11-06 , DOI: 10.1038/nrd.2017.201
Daniella M. Schwartz , Yuka Kanno , Alejandro Villarino , Michael Ward , Massimo Gadina , John J. O'Shea

JAK inhibition as a therapeutic strategy for immune and inflammatory diseases

JAK inhibition as a therapeutic strategy for immune and inflammatory diseases, Published online: 06 November 2017; doi:10.1038/nrd.2017.201

NatureArticleSnippet(type=short-summary, markup=

Janus kinases (JAKs) are essential signalling mediators downstream of many pro-inflammatory cytokines. Jakinibs — small-molecule inhibitors of JAKs — have gained traction as safe and efficacious options for the treatment of inflammation-driven pathologies. This Review discusses the biology, development and efficacy of jakinibs in the treatment of immune and inflammatory diseases.

, isJats=true)

中文翻译：